UBRELVY® OFFERS PATIENTS THE FLEXIBILITY OF:

16-pack of 100 mg tablets

Sixteen 100 mg tablets in 1 prescription
Allows patients to have pills on hand when they need them most1

Optional second dose

Optional second dose
Gives your patients the confidence to treat persistent attacks1

50 mg and 100 mg doses

2 dosage strengths
The only gepant available in 50 mg and 100 mg tablets1,2

Dosing packets

Convenient on-the-go packs
UBRELVY can always be on hand, anywhere patients need their acute treatment1

MIGRAINE ATTACKS CAN BE UNPREDICTABLE3—HELP MAKE SURE YOUR PATIENTS ARE READY. UBRELVY IS THE ANYTIME, ANYWHERE MIGRAINE MEDICINE™ THAT OFFERS THE FLEXIBILITY YOUR PATIENTS DESERVE1

The Anytime, Anywhere Migraine Medicine™

UBRELVY is taken orally, with or without food.1 A second dose can be taken at least 2 hours after the initial dose, if needed.1 The maximum UBRELVY dose in a 24-hour period is 200 mg.1 The safety of treating more than 8 migraines in a 30-day period has not been established1

DOSING CONSIDERATIONS

Drug Interactions

  • UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they will cause an increase in UBRELVY exposure1
  • Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of UBRELVY exposure1
  • Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications. See Section 2.2 of the Prescribing Information1
  • Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice; avoid second dose within 24 hours1

Use in Specific Populations

  • Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (CLcr 15-29 mL/min): recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose1
  • Avoid use in patients with end-stage renal disease (CLcr <15 mL/min)1

Use With Preventive Medications

  • In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline.1,4 None of these patients were on concomitant preventive medications that act on the CGRP pathway1